Stocks · News reference
SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZeneca
SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (NYSE:AZN).This
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Sophia Genetics (NASDAQ:SOPH) with a Buy and maintains $14 price target.
SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology